Nanoencapsulation Platform Drug Candidates
Broad Range of Cancers
Discovery/PreclinicalActive R&D
Key Facts
About Fulgent Genetics
Founded in 2011, Fulgent Genetics has grown from a focused genetic testing lab into a comprehensive precision medicine company, merging a vast diagnostic services business with an emerging therapeutic development arm. Its strategic acquisitions, including Bako Diagnostics and StrataDx, have expanded its capabilities into anatomic pathology and solidified its market position. The company's mission is to develop flexible and affordable diagnostics and therapeutics to improve patient outcomes across oncology, rare diseases, and reproductive health.
View full company profileTherapeutic Areas
Other Broad Range of Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| GLIX5 | Hemispherian | Proof-of-Concept |